黄体中期血清雌二醇水平与激素替代治疗冻融胚胎移植周期活产率相关:一项队列研究
该前瞻性观察队列纳入2020年1月至2022年11月共412例激素替代治疗冻融胚胎移植单囊胚移植女性,按囊胚移植日血清雌二醇水平分组。雌二醇≥292且<409 pg/mL组活产率为59%(60/102),低于292 pg/mL组为39%(101/260),≥409 pg/mL组为28%(14/50)。调整混杂后,雌二醇过低或过高均与活产风险降低相关,仅25%患者处于最佳范围。
要点
- 囊胚移植日血清雌二醇≥292且<409 pg/mL时活产率最高,为59%(60/102)。
- 雌二醇<292 pg/mL组活产率39%,≥409 pg/mL组28%,均显著低于最佳范围组。
- 调整后活产风险差:<292 pg/mL组为-0.21(-0.32;-0.10),≥409 pg/mL组为-0.31(-0.45;-0.18)。
核心结论
- 在确保最佳血清孕酮水平的激素替代治疗冻融胚胎移植队列中,黄体中期血清雌二醇水平与活产率显著相关,雌二醇水平既不宜过高也不宜过低。
研究设计与样本
- 前瞻性观察队列研究,纳入2020年1月至2022年11月共412例接受激素替代治疗冻融胚胎移植单囊胚移植的女性,来自公共生殖门诊。
主要发现
- 与持续妊娠相关的最佳血清雌二醇范围为≥292 pg/mL且<409 pg/mL(≥1,070 pmol/L且<1,500 pmol/L)。
- 雌二醇在最佳范围组活产率为59%(60/102),<292 pg/mL组为39%(101/260),≥409 pg/mL组为28%(14/50)。
- 调整孕酮水平、体质指数、取卵年龄、第5天或第6天玻璃化囊胚及囊胚评分后,与最佳范围相比,<292 pg/mL组活产调整风险差为-0.21(-0.32;-0.10),≥409 pg/mL组为-0.31(-0.45;-0.18)。
- 仅25%患者雌二醇水平处于最佳范围。
关键数值与推荐
- 激素替代治疗冻融胚胎移植周期 priming 方案为口服雌二醇6mg/24小时(晚间给药),随后阴道孕酮400mg/12小时。
- 囊胚移植日(孕酮给药第6天)在末次孕酮给药后2-4小时、末次雌二醇给药后9-14小时测定血清雌二醇和孕酮。
- 移植日血清孕酮<11 ng/mL(35 nmol/L)者额外接受直肠孕酮400mg/12小时,未额外追加雌二醇剂量。
临床怎么用
- 作者认为黄体中期血清雌二醇水平与激素替代治疗冻融胚胎移植周期活产率相关,雌二醇水平既不应过高也不应过低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study whether midluteal serum estradiol (E2) levels are associated with the live birth rate in hormone replacement therapy frozen embryo transfer (HRT-FET) cycles in patients with optimal midluteal serum progesterone (P4) levels. DESIGN: Observational prospective cohort study. SETTING: Public fertility clinic. PATIENTS: A total of 412 women had an HRT-FET cycle single blastocyst transfer from January 2020 to November 2022. INTERVENTION: The HRT-FET cycle priming regimen included oral E2 (6mg/24 h) administered in the evening, followed by vaginal P4 (400mg/12 h). Serum E2 and P4 levels were measured using a standardized method, 2-4 hours after the latest P4 administration and 9-14 hours after E4 administration on the day of blastocyst transfer, day 6 of P4 administration. Patients with serum P4 levels (<11 ng/mL [35 nmol/L]) on the day of transfer received additional rectal P4 (400mg/12 h). No additional E2 dose was administered. MAIN OUTCOME MEASURES: The primary outcome was the live birth rate (LBR) in relation to E2 levels at blastocyst transfer day. RESULTS: The optimal serum E2 levels correlating with ongoing pregnancy were ≥292 pg/mL and <409 pg/mL (≥1,070 pmol/L and <1,500 pmol/L). The LBR was 59% (60/102) when E2 levels were within this range, whereas a significantly lower LBR of 39% (101/260) was seen in patients when E2 levels were <292 pg/mL (<1,070 pmol/L) and of 28% (14/50) when E2 levels were ≥409 pg/mL (≥1,500 pg/mL). In a logistic regression analysis, adjusting for serum P4 level ≥11 ng/mL or <11 ng/mL (≥35 nmol or <35 nmol/L) on the day of transfer, body mass index, age at oocyte retrieval, day 5 or 6 vitrified blastocysts, and blastocyst score, the adjusted risk difference of live birth was -0.21 (-0.32; -0.10) when the E2 level was <292 pg/mL (<1,070 pmol/L) and -0.31 (-0.45; -0.18) when the E2 level was ≥409 pg/mL (≥1,500 pmol/L) compared with E2 levels ≥292 pg/mL and <409 pg/mL (≥1,070 and <1,500 pmol/L). Importantly, only 25% of patents had optimal levels. CONCLUSION: The study shows a significant association between serum E2 levels and reproductive outcomes in an HRT-FET cohort in which optimal serum P4 levels were secured. Midluteal serum E2 levels are associated with the LBR in HRT-FET cycles, and E2 levels should neither be too high nor too low. CLINICAL TRIAL REGISTRATION NUMBER: EudraCT No.: 2019-001539-29.
引用
- Alsbjerg B, Jensen MB, Elbaek HO, et al. Midluteal serum estradiol levels are associated with live birth rates in hormone replacement therapy frozen embryo transfer cycles: a cohort study. Fertil Steril. 2024. PMID: 38604265. doi:10.1016/j.fertnstert.2024.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。